RT Journal Article
T1 Sentinel lymph node biopsy in breast cancer after neoadjuvant therapy using a magnetic tracer versus standard technique: A multicentre comparative non-inferiority study (IMAGINE-II)
A1 Gimenez-Climent, Julia
A1 Marin-Hernandez, Caridad
A1 Fuster-Diana, Carlos A.
A1 Torro-Richart, Jose A.
A1 Navarro-Cecilia, Joaquin
A1 Grp Estudios Senologicos Soc Espan, 
K1 Breast cancer
K1 Sentinel lymph node biopsy (SLNB)
K1 Superparamagnetic iron oxide (SPIO)
K1 Sentimag
K1 Neoadjuvant therapy
K1 Total tumour load (TTL)
K1 Superparamagnetic iron-oxide
K1 Preoperative chemotherapy
K1 Sentimag
K1 Carcinoma
K1 Guideline
K1 Trial
K1 Tc-99
AB Introduction: Previous studies have shown that a magnetic tracer technique using superparamagnetic iron oxide (SPIO) and a manual magnetometer (Sentimag, SM) is as effective as the standard technique using a radioisotope injection and a gamma probe (GP) for the detection of sentinel lymph nodes (SLNs) in breast cancer (BC) patients. This study was designed to investigate the performance of SM for post-neoadjuvant (NAT) SLN biopsy in BC patients.Materials and methods: Post-NAT BC patients were recruited from five centres. Readings of SLNs were recorded in transcutaneous, intraoperative and ex vivo scenarios by both GP and SM techniques. SLNs were assessed by OSNA (One-Step Nucleic Acid Amplification).Results: A total of 89 patients were included. At the patient level, the transcutaneous and intraoperative SLN detection rate was 97.8% by both techniques. At the node level, the GP detection rate intraoperatively was lower than that of SM (93.8% vs. 99.2%), with a concordance rate of 93% (90% CI 1.25; 9.44). The ex vivo detection rate was lower for GP compared to SM both per patient 96.6% vs. 97.8%, and per node 90.6% vs. 98.4% (90% CI-2.03; 4.22 and 1.82; 13.68, respectively). Furthermore, the detection rate of pathologically positive SLNs per patient and per node was lower for GP than SM both intraoperatively and ex vivo. These results showed the non-inferiority of SM intraoperatively per node (90% CI-4.89; 20.89) and ex vivo per patient (90% CI-2.38; 29.66).Conclusion: Our study showed the non-inferiority of SM compared to GP for detecting SLNs in post-NAT BC patients. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of Surgical Associates Ltd.
PB Elsevier sci ltd
SN 2405-8572
YR 2021
FD 2021-09-03
LK https://hdl.handle.net/10668/26583
UL https://hdl.handle.net/10668/26583
LA en
DS RISalud
RD Apr 17, 2025